Pharmaceutical industry executives are rejecting claims that artificial intelligence will cure most diseases within a decade, citing a regulatory reality check: the FDA has approved zero biotech drugs designed using AI.
The skepticism cuts to the core economics of drug development. A single therapy requires 10 to 15 years and billions in capital to move from discovery through clinical trials to regulatory clearance. Failure rates remain high throughout this gauntlet. No AI system has compressed this timeline materially—and the regulatory approval process itself, which tests efficacy and safety in human subjects, remains largely unmoved by computational advances.
AI has proved useful in early-stage work: target identification, molecule screening, compound optimization. But pharma executives emphasize that these represent only a fraction of the total program cost and timeline. The constraint is not computational speed. It is the requirement for extensive human validation to satisfy FDA standards before any drug reaches patients.
Until at least one AI-designed candidate clears regulatory review, claims about significant speedup remain speculative. The industry has seen incremental efficiency gains. Fundamental acceleration of the clinical pathway has not materialized.
